ginkgo bioworks similar companies

Ginkgo Bioworks (NYSE:DNA) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the superior stock? However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Contact Us Submit a Company Merz North America. to let us know you're having trouble. Healthcare - Public. Be the first to gain access. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. [20], On 4 October 2022, it was reported that Ginkgo Bioworks would acquire France-based adaptive laboratory evolution instruments developer Altar and California-based Circularis to strengthen capabilities in cell and gene therapy. We aim to bring you long-term focused analysis driven by fundamental data. Agrivida scientists are experts in biochemistry, plant biology, molecular biology, agriculture, and nutrition. Bayer and Ginkgo Bioworks close deal creating Agricultural Biologicals Get Ginkgo Bioworks News Delivered to You Automatically. I generally consider insider ownership to be a good thing. Wir entschuldigen uns fr die Umstnde. A Perfume That Smells Like RosesBut Is Actually Made from Yeast. Northeast Pharmaceutical Group. Over the last few years, Ginkgo has gone through impressive growth and now has close to 1,200 staff after the recent acquisition of Zymergen. This can indicate that the company has a certain degree of credibility in the investment community. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can check here to see if those insiders have been buying recently. DAB.bio offers FAST to boost fermentation based production. The definition of company insiders can be subjective and does vary between jurisdictions. CIT also provides contract development, toll manufacturing and biotransformation services. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Our data indicates that hedge funds own 11% of Ginkgo Bioworks Holdings. We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends. Als u dit bericht blijft zien, stuur dan een e-mail Over the last year, Ginkgo has been making moves into biopharma, and now they have announced a new Enzyme Intelligence service. Learn more. Other companies like Cradle, Biomatter Designs, Cambrium, Arzeda, and Basecamp Research are also using the power of machine learning and AI to design novel enzymes or improve existing ones. Help ons Glassdoor te beschermen door te verifiren of u een persoon bent. I recently chatted with Jason Kelly, one of Ginkgos co-founders and current CEO, who will be speaking at SynBioBeta 2023, to get more details on the companys latest offering. Top 5 EV Tech Stocks to Buy for 2023 Terms and Conditions We believe the future production of chemicals and fuels that we use every day is rooted in biobased alternatives. 27 Drydock Avenue, 8th Floor Currently, Ginkgo Bioworks Holdings Inc does not have a price-earnings ratio. Real-time analyst ratings, insider transactions, earnings data, and more. Our bioreactor works for all types of feedstock, whether its sugar (1st or 2nd generation), gas, or other types of feedstock. Ginkgo Bioworks has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Ginkgo says its database currently contains close to 1 billion sequences, and all that wealth of genetic information is available to their customers: It's just a service contract away from anybody that wants to develop a product, says Kelly. We succeed when our customers succeed is the philosophy Ginkgo is banking on. Listing for: Ginkgo Bioworks. naar para nos informar sobre o problema. Furthermore, Ginkgo Bioworks Holdings Inc. (DNA)s beta value is 1.04, and its average true range (ATR) is 0.14. 337927). What we really want to drive home to our customers is that you dont need to do it yourself we have invested half a billion dollars into infrastructure and automation so you dont have to, says Kelly. In addition to engaging in strategic partnerships to tailor their bioprocess services for clients, they also license their proprietary bioprocess technologies. COMING SOON - New MarketBeat All Access tools are being released on Monday. Ginkgo Bioworks's primary competitors include Regeneron, AbCellera, Manus Bio and 8 more. You must have cookies enabled to login Have feedback on this article? It seems insiders own a significant proportion of Ginkgo Bioworks Holdings, Inc.. But engineering living cells is hardevolution is four billion years ahead of us, after all. . site you are consenting to these choices. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. verdade. By harnessing the power of biology, Arcaea is poised to produce highly sustainable products that can deliver new functionality and performance across skincare, bodycare, haircare, and aesthetics. Ginkgo Bioworks was founded in 2008 with the mission to make biology easier to engineer. message, contactez-nous l'adresse Our data reflects individual insiders, capturing board members at the very least. Integrated software and automated tools allow for scaling up our process while scaling down costs. It offers a layer of unified data intelligence and controls across all major public clouds, data clouds, software as a service (SaaS), and private clouds. Zymergen is a molecular technology company ushering in a new age of manufacturing and industrial innovation. Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. They apply synthetic biology to the manufacture of industrial products including enhanced biofuels, sustainable manufacturing of chemicals and the production of protein therapeutics. [14][15][self-published source] The investment management firm Baillie Gifford became the largest shareholder (15%) with the purchase of 167.75million shares on 31 March 2022. We are a start-up based on technology developed at the University of Toronto. Ginkgo Bioworks Holdings Inc. (NYSE:DNA) shares, rose in value on Wednesday, 07/05/23, with the stock price up by 3.93% to the previous days close as strong demand from buyers drove the stock to $1.85. In the chart below, we zoom in on the different ownership groups of Ginkgo Bioworks Holdings. "the organism company," has notched many milestones in its 13-year history. But engineering living cells is hard-evolution is four billion years ahead of us, after all. Aiutaci a proteggere Glassdoor dimostrando che sei una persona reale. Healthcare . This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. About Us G The main competitors of Ginkgo Bioworks include Denali Therapeutics (DNLI), Vir Biotechnology (VIR), Krystal Biotech (KRYS), CRISPR Therapeutics (CRSP), Revolution Medicines (RVMD), Immunocore (IMCR), Vaxcyte (PCVX), ProKidney (PROK), Halozyme Therapeutics (HALO), and Immunovant (IMVT). Willow Biosciences (TSX: WLLW) (OTCQB: CANSF) provides a research platform that reinvents the production of active pharmaceutical ingredient (API) supplies for global p. Biology is incredibly complex, so every model-generated sequence still needs to be tested in the lab. We grew out of the TEEC Angel Fund, which made seed-stage, highly successful bets on companies like Zoom Communications, Quanergy, Iterable, Carta, Plus.ai . Ginkgo Bioworks is saying drop all that: That's the big shift we're trying to create in the market. Ginkgo Bioworks banner on the faade of the New, A row of bioreactors for growing microbial. We did some more digging and found that 7 of the top shareholders account for roughly 52% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat. Ginkgo Bioworks has 5 employees at their 1 location. Further, Ginkgo Bioworks Holdings Inc. (DNA) has a beta value of 1.00, and an average true range (ATR) of 0.14. Biology is weird and whimsical, and we celebrate that. Aydanos a proteger Glassdoor verificando que eres una persona real. All Rights Reserved. Also referred to as "smart money", institutions have a lot of sway over how a stock's price moves. Comparatively, 7.9% of Denali Therapeutics shares are owned by insiders. Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. The company's organism engineers work directly with customers, including Fortune 500 companies, to design microbes . Denali Therapeutics received 401 more outperform votes than Ginkgo Bioworks when rated by MarketBeat users. Denali Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. Analysts have given the company's stock an average 52-week price target of $4.24, forecast between a low of $1.25 and high of $12.00. The company was founded in 2015 and is based in South San Francisco, California. It would appear that 11% of Ginkgo Bioworks Holdings shares are controlled by hedge funds. We grew out of the TEEC Angel Fund, which made seed-stage, highly successful bets on companies like Zoom Communications, Quanergy, Iterable, Carta, Plus.ai, Opentrons, WeRide.ai and Ginkgo Bioworks, all subsequent Unicorns. Privacy Policy Ginkgo Bioworks presently has a consensus target price of $4.05, suggesting a potential upside of 128.81%. Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. Elaine Watson. DOD Consultant's big 2024 prediction looks to be coming true, Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation, [BREAKING] Small Firm Develops World's First Anti-Aircraft Laser, Wall Street legend warns: "A new dawn is coming", WARNING: These 110 Banks Are Planning to Replace the U.S. Dollar, Why 2023 Could Kick Off a "Cash Frenzy" in Stocks. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. [16], On 14 March 2022, it was reported that Ginkgo Bioworks signed a Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform. Ginkgo promises not only to take that work off their hands but do it better and faster. contact@marketbeat.com B. Riley Wealth Advisors Inc. Acquires New Position in Ginkgo Bioworks Codexis' proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Get short term trading ideas from the MarketBeat Idea Engine. Each company is represented with a line over a 90 day period. This may not be consistent with full year annual report figures. 'Unknown laser company making HUGE profit from Russia-Ukraine War'. With an ownership of 7.3%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Product Manager Job San Jose California USA,IT/Tech - Learn4Good The stocks technical analysis shows that the PEG ratio is about 0, with the price of DNA currently trading nearly 2.66% and 20.47% away from the simple moving averages for 20 and 50 days respectively. democratizes access to genetic information. A growing. enviando un correo electrnico a Institutional owners may consider drastic measures as Ginkgo Bioworks "Ginkgo helps companies across industries use synthetic biology to produce better, more sustainable products," said Jason Kelly, CEO at Ginkgo Bioworks. Our main focus is what is inside our technology the clients micro-organism. About - Ginkgo Bioworks Oura develops a wellness ring and application designed to help users get restful sleep. Cell Therapy Services, Virtual Event: Functional Food Proteins with Microbial Expression Systems, Developing A More Scalable Enzymatic Process for Allulose with Ambrosia Bio. Independent Director of Ginkgo Bioworks Holdings Shyam Sankar Buys 32% You can read more about your cookie choices at our privacy policyhere. As a full-stack synthetic biology service provider, Ginkgo does everything: from developing new flavors and fragrances to engineering entire organisms for crop treatments and living medicines. Directory of Companies. Your email address will not be published. Scientists and Engineers at Conagen use the latest synthetic biology tools to design metabolic pathways, improve production organisms, optimize production procedures, and ensure the quality as well as safety of the final products. per informarci del problema. Put another way, the group faces the maximum upside potential (or downside risk). Founded in 2003 , Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. In addition, we found that Jason Kelly, the CEO has 4.4% of the shares allocated to their name. Now imagine. . Microbial Stem Cells divide asymmetrically, self-renewing themselves, and generating new young and productive cells. This may not be consistent with full year annual report figures. Securiti develops privacy management software. Wenn Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. "I've been at Ginkgo for over 5 years and the best part is it still doesn't feel like 'work.' Party on . CBI websites generally use certain cookies to enable better interactions with our sites and services. Reshma Shetty co-founded Ginkgo Bioworks in 2008. Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, [3] headed by Jason Kelly. As a result, investors might want to see an improvement in the stock's price before the company announces its earnings report. The Boston genetic engineering company Ginkgo Bioworks and its CEO, Jason Kelly, have been spectacularly successful selling a story: that synthetic biology will transform the manufacture of.

Parents Don't Want Me To Be Independent, St Elizabeth University Baseball Schedule 2023, Sammy Maloof Daughters Age, Police Auctions - Salt Lake City, Articles G